Lonza has completed the planned expansion of its Solid Form Services (SFS) offering for small molecule drugs at its facility in Bend, OR, which became fully operational in 4Q22. The expansion enhances Lonza’s capabilities in meeting accelerated timelines for increasingly complex molecules.   The expanded facility includes remodeled and dedicated lab space which is primarily being used to support biotech and midsize pharma companies in developing early-stage compounds. It can support all ...